Skip to main content

Advertisement

Table 1 Patient characteristics, disease measures, and serum levels of Pro-C2 and C-Col10

From: Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis

  axSpA (n = 110) PsA (n = 101) Control
Male sex, % 72 % 59 %  
Age, years 36.6 (35.3–38.0) 37.0 (35.6–38.5)  
BMI, kg/m2 25.5 (24.8–26.3) 27.4 (26.2–28.5)  
Smoker, % 36 % 35 %  
HLA-B27 positive, % 87 % 20 %  
Disease duration, years 6.4 (5.4–7.5) 6.7 (5.6–7.8)  
VAS    
 Patient global 34 (29–39) 39 (34–45)  
 Patient pain 32 (27–37) 32 (27–37)  
 Patient fatigue 40 (34–45) 43 (37–49)  
 Physician global 4 [1–16] 3 [1–14]  
BASDAI 31 (26–35) 36 (31–41)  
BASFI 23 (19–27) 27 (22–32)  
BASMI 10 [0–20] 10 [0–10]  
ASDAS (CRP) 2.0 (1.8–2.3) 2.1 (1.9–2.4)  
Swollen joints, % 9 % 38 %  
hs-CRP, mg/dl 3 [1–7] 3 [1–9]  
Pro-C2, ng/ml 1.11 [0.67-1.64] 1.03 [0.53-1.47] 0.30 [0.16-0.41]
Col-X, ng/ml 0.45 [0.28-0.67] 0.42 [0.31-0.72] 0.33 [0.31-0.45]
  1. Abbreviations: ASDAS Ankylosing Spondylitis Disease Activity Score, axSpA axial spondyloarthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BMI body mass index, HLA-B27 human leukocyte antigen B27, hs-CRP high-sensitivity C-reactive protein, PsA psoriatic arthritis, VAS visual analogue scale
  2. Data are presented as mean (95 % CI) for variables with a normal distribution and as median [25th–75th percentile range] for variables that were not normally distributed